Erratum: A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma (Blood (2019) 133: 11 (1201-1204) DOI: 10.1182/blood-2018-11-886457)

P. Martin; N. L. Bartlett; K. A. Blum

doi:10.1182/blood.2019002741

Erratum: A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma (Blood (2019) 133: 11 (1201-1204) DOI: 10.1182/blood-2018-11-886457)

P. Martin, N. L. Bartlett, K. A. Blum

Research output: Contribution to journal › Comment/debate

Abstract

In the conflict-of-interest disclosure paragraph on page 1203, the sentence “S.C.-K. served as a consultant for Vigilant.” is incorrect. Author Selina Chen-Kiang had no competing financial interests to declare. The error has been corrected in the online version of the article.

Original language	English
Pages (from-to)	908
Number of pages	1
Journal	Blood
Volume	134
Issue number	11
DOIs	https://doi.org/10.1182/blood.2019002741
State	Published - Sep 12 2019

Access to Document

10.1182/blood.2019002741

Cite this

@article{ae0d97bff81448348f971cfe7df9dbf3,

title = "Erratum: A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma (Blood (2019) 133: 11 (1201-1204) DOI: 10.1182/blood-2018-11-886457)",

abstract = "In the conflict-of-interest disclosure paragraph on page 1203, the sentence “S.C.-K. served as a consultant for Vigilant.” is incorrect. Author Selina Chen-Kiang had no competing financial interests to declare. The error has been corrected in the online version of the article.",

author = "P. Martin and Bartlett, {N. L.} and Blum, {K. A.}",

note = "Publisher Copyright: {\textcopyright} 2019 by The American Society of Hematology.",

year = "2019",

month = sep,

day = "12",

doi = "10.1182/blood.2019002741",

language = "English",

volume = "134",

pages = "908",

journal = "Blood",

issn = "0006-4971",

number = "11",

}

TY - JOUR

T1 - Erratum

T2 - A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma (Blood (2019) 133: 11 (1201-1204) DOI: 10.1182/blood-2018-11-886457)

AU - Martin, P.

AU - Bartlett, N. L.

AU - Blum, K. A.

PY - 2019/9/12

Y1 - 2019/9/12

N2 - In the conflict-of-interest disclosure paragraph on page 1203, the sentence “S.C.-K. served as a consultant for Vigilant.” is incorrect. Author Selina Chen-Kiang had no competing financial interests to declare. The error has been corrected in the online version of the article.

AB - In the conflict-of-interest disclosure paragraph on page 1203, the sentence “S.C.-K. served as a consultant for Vigilant.” is incorrect. Author Selina Chen-Kiang had no competing financial interests to declare. The error has been corrected in the online version of the article.

UR - http://www.scopus.com/inward/record.url?scp=85072150020&partnerID=8YFLogxK

U2 - 10.1182/blood.2019002741

DO - 10.1182/blood.2019002741

M3 - Comment/debate

C2 - 31515230

AN - SCOPUS:85072150020

VL - 134

SP - 908

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -

Erratum: A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma (Blood (2019) 133: 11 (1201-1204) DOI: 10.1182/blood-2018-11-886457)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this